Gossamer Bio, Inc. (GOSS)
0.1664
-0.01
(-3.65%)
USD |
NASDAQ |
Sep 03, 10:42
Gossamer Bio Research and Development Expense (TTM) : 163.94M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 163.94M |
| March 31, 2026 | 179.10M |
| December 31, 2025 | 174.07M |
| September 30, 2025 | 161.14M |
| June 30, 2025 | 150.30M |
| March 31, 2025 | 143.57M |
| December 31, 2024 | 137.67M |
| September 30, 2024 | 131.34M |
| June 30, 2024 | 127.45M |
| March 31, 2024 | 128.46M |
| December 31, 2023 | 133.65M |
| September 30, 2023 | 145.02M |
| June 30, 2023 | 158.27M |
| March 31, 2023 | 164.37M |
| December 31, 2022 | 168.72M |
| September 30, 2022 | 167.76M |
| June 30, 2022 | 166.04M |
| Date | Value |
|---|---|
| March 31, 2022 | 167.55M |
| December 31, 2021 | 166.84M |
| September 30, 2021 | 164.44M |
| June 30, 2021 | 162.79M |
| March 31, 2021 | 157.04M |
| December 31, 2020 | 156.59M |
| September 30, 2020 | 159.02M |
| June 30, 2020 | 158.24M |
| March 31, 2020 | 156.02M |
| December 31, 2019 | 140.31M |
| September 30, 2019 | 126.05M |
| June 30, 2019 | 105.01M |
| March 31, 2019 | 77.44M |
| December 31, 2018 | 55.24M |
| September 30, 2018 | 30.05M |
| June 30, 2018 | 11.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arbutus Biopharma Corp. | 17.80M |
| Kura Oncology, Inc. | 259.47M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |